Pleasanton, Calif., March 5, 2026, 02:32 PST
- Veeva is projecting fiscal 2027 revenue between $3.585 billion and $3.6 billion, while first-quarter revenue lands in a range of $855 million to $858 million.
- Revenue for the fourth quarter climbed 16% to $836M, while adjusted EPS came in at $2.06.
- The company kicked off a $2B buyback program, starting purchases back in January.
Veeva Systems Inc (VEEV) guided for fiscal 2027 revenue between $3.585 billion and $3.600 billion, targeting first-quarter sales of $855 million to $858 million. In the fourth quarter, revenue climbed 16% to $836 million, with subscription revenue hitting $707.7 million. Adjusted earnings, which strip out stock-based compensation and other items, landed at $2.06 a share. “Results exceeded our guidance across the board,” CFO Brian Van Wagener said. CEO Peter Gassner flagged the company’s pivot to “agentic” software — AI agents that take action within applications — as a “substantial opportunity” as Veeva launches its updated Vault CRM and introduces AI agents, the first of which debuted in December. Veeva Investor Relations
The forecast is key: Veeva’s customers—drugmakers and biotech companies—usually stick with spending on core subscription software, even when tech budgets elsewhere get shaky. A weaker projection would have sent up a red flag for this corner of enterprise software, which is often viewed as a defensive play.
Veeva is in the middle of revamping sections of its commercial stack—while it works to layer in fresh AI features. The company’s also trying to keep service costs from ballooning and doesn’t want customer migrations to bog down.
Veeva’s numbers topped forecasts, per an Associated Press earnings snapshot citing data from Zacks. The consensus from Zacks analysts called for adjusted earnings of $1.92 a share on $808.9 million in revenue. Veeva, instead, posted a quarterly profit of $244.2 million, or $1.45 per share, while full-year profit landed at $908.9 million on roughly $3.2 billion in revenue.
Veeva, in prepared remarks, disclosed it kicked off its first share buyback program in January, with board approval for up to $2 billion in repurchases over a two-year window. During the quarter, the company picked up roughly 0.8 million shares for about $180 million. As of year-end, cash and short-term investments stood at $6.6 billion. “Normalized billings”—an internal measure adjusting invoiced sales for things like contract-term shifts or delayed renewals—came in at $1.506 billion for the quarter, up 18%. Veeva plans to stop issuing quarterly billings guidance, shifting to full-year normalized billings updates alongside other key numbers.
Veeva’s pitch around AI isn’t just another chatbot stapled to a dashboard, the company insists. These agents are built to automate pieces of regulated workflows—compliance checks and audit trails aren’t extras; they’re baked in from the start.
Veeva delivers cloud-based software, data, and consulting services for life sciences worldwide, covering everything from research and development to quality and commercial operations. The company divides its lineup into Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud, all anchored by its Vault platform.
Veeva will be sized up against its larger rivals, as investors eye how enterprise software titans like Salesforce and Oracle continue expanding their suite of cloud offerings tailored to industries. Health data firms such as IQVIA, meanwhile, have taken to layering more software on top of their clinical and commercial solutions. Veeva counters with a focus on specialization—and operational systems clients rarely swap out.
Still, there are the usual risks to watch for. Pharma IT budgets could shrink, and customers might take their time shifting to newer offerings. If AI agents gain traction unevenly, growth and margins could feel the squeeze—even if demand doesn’t collapse.
Veeva hasn’t budged from its $6 billion revenue run-rate goal for 2030. The company’s bet on AI and CRM will get tested over the next few quarters, as it becomes clearer whether those initiatives can actually fuel growth—or end up as extra costs customers decide to postpone.
